International Endovascular Corporation (IEVC) Acquires DABRA™ Laser System to Advance Treatment of Peripheral Artery Disease

Acquisition positions IEVC to reintroduce proven plaque ablation laser technology for PAD and expand future vascular applications

Carlsbad, CA – April 28, 2026

International Endovascular Corporation (IEVC), a medical technology company focused on advancing next-generation vascular therapies, today announced the acquisition of the DABRA™ Laser and Catheter System from Catheter Precision, the successor company to Ra Medical Systems.

The acquisition includes all related assets, including FDA 510(k) clearances, intellectual property, clinical data, trademarks, patents, and regulatory and manufacturing documentation. IEVC intends to reintroduce DABRA to the market, expanding access to its minimally invasive laser technology for the treatment of peripheral artery disease (PAD).

The DABRA Laser System utilizes a proprietary catheter-based system delivering 308 nm excimer laser energy to ablate arterial blockages—ranging from thrombus to heavily calcified plaque—into their constituent chemical components. This mechanism of action minimizes the risk of distal embolization while preparing the vessel for adjunctive therapies such as low-pressure balloon angioplasty.

IEVC is supported by a team of former key personnel from Ra Medical Systems with deep expertise in the development, commercialization, and clinical application of DABRA technology. The company is positioned to re-establish the platform among interventional physicians, many of whom are already familiar with its clinical performance and outcomes.

“Every cath lab should have a DABRA laser atherectomy device because of its unique properties,” said Dr. Athar Ansari, MD, a pioneer in minimally invasive outpatient-based treatment for PAD.

Peripheral artery disease is a significant and growing global health challenge. Approximately 1 in 20 older Americans are affected by PAD, and the number of patients is projected to increase by over 200% by 2050. Plaque modification and vessel preparation technologies such as DABRA continue to play a critical role in improving procedural outcomes.

In a recent systematic review and meta-analysis, Carr et al. concluded that atherectomy technologies play an important role in vessel preparation and may improve procedural outcomes.

Dean Irwin, Founder and Chief Executive Officer of IEVC, commented: “DABRA has played a critical role in improving outcomes for patients with peripheral artery disease, including limb salvage in complex cases. With this acquisition, we are bringing together the experienced team, technical expertise, and operational infrastructure needed to reintroduce this important technology to physicians and their patients. Beyond PAD, there is strong interest among physicians in expanding DABRA’s application into additional vascular territories, including coronary disease. We look forward to advancing the platform and exploring its full clinical potential.”

About International Endovascular Corporation (IEVC)

International Endovascular Corporation (IEVC), founded in May 2024, is focused on advancing innovative technologies for the treatment of vascular disease. The company is operated by CyMeda, Inc., a developer of laser and light-based medical devices founded in July 2020. To learn more about IEVC, please visit https://www.ievcorp.com

Contact:

Dean Irwin, CEO

dean.irwin@ievcorp.com

Reference:

Carr JG, et al. J Soc Cardiovasc Angiogr Interv. 2025;4(11):104009.